In This Issue….                                                                           

-   In certain people, B2 lowers blood pressure better than meds
-   Evidence mounts for therapeutic use of co Q10 in Parkinson’s patients
-   Vitamin D repletion lowers the inflammatory marker CRP
-   Vitamin C protects against toxicity from common antibiotic
-   Micronutrient supplementation shows promise for adults with ADHD

CLINICAL UPDATE – In certain people, B2 lowers blood pressure better than meds

In this randomized trial of 1427 people with hypertension, those with the MTHFR (methylene tetrahydrofolate reductase) 677TT gene responded to riboflavin (vitamin B2) supplementation with a reduced systolic blood pressure compared to placebo. In fact, despite being prescribed high blood pressure medication, most participants with this gene still did not reach their blood pressure goal. However, when given vitamin B2, blood pressure did decrease, leading researchers to conclude “that riboflavin supplementation targeted at hypertensive individuals with the MTHFR 677TT genotype can decrease BP more effectively than treatment with current antihypertensive drugs only and indicate a personalized approach to the management of hypertension in this genetically at-risk group.”
(Hypertension, June 2013)

LINK to ABSTRACT Blood pressure in treated hypertensive individuals with the MTHFR 677TT genotype is responsive to intervention with riboflavin: findings of a targeted randomized trial.

CLINICAL UPDATE – Evidence mounts for therapeutic use of coQ10 in Parkison’s patients

Sixteen patients with early Parkinson’s disease were given progressively higher doses of coenzyme Q10 daily for two weeks. Dosages ranged from 400, 800, 1200 and 2400 mg/day. All dosages of coQ10 were well tolerated and clinical improvements were seen upon completion of the study, particularly in patients whose baseline coenzyme Q10 levels were the lowest. In an unrelated animal study, researchers found that orally administered coQ10 blocked the progression of neurodegeneration when administered therapeutically stating “such unprecedented neuroprotection had never been reported before.”
(Antioxidants and Redox Signaling, February 2014)
(BMC Neuroscience, January 2014)

LINK to ABSTRACT Does High-Dose Coenzyme Q10 Improve Oxidative Damage and Clinical Outcomes in Parkinson's Disease?
LINK to ABSTRACT Orally delivered water soluble Coenzyme Q10 (Ubisol-Q10) blocks on-going neurodegeneration in rats exposed to paraquat: potential for therapeutic application in Parkinson's disease. LINK to FREE FULL TEXT

CLINICAL UPDATE – Vitamin D repletion lowers inflammatory marker CRP

In this study, 218 overweight women with vitamin D levels below 32ng/mL (classified as deficient) were assigned to a weight loss regimen. Half of the women took 2000IU of vitamin D daily while the other half took a placebo. At the end of the study, the women who became replete in vitamin D through better compliance (as measured by pill count), lost more weight. Markers of insulin, waist size and body fat percentage were similar in the two groups but those who took vitamin D also showed a much higher reduction (46% reduction vs 25% reduction) in the inflammatory marker CRP (C-reactive protein).(American Journal of Clinical Nutrition, March 2014)

LINK to ABSTRACT Vitamin D3 supplementation during weight loss: a double-blind randomized controlled trial. 

CLINICAL UPDATE – Vitamin C protects against toxicity from common antibiotic

When gentamicin, a common antibiotic, was administered with vitamin C versus alone, markers of oxidative stress specifically with respect to kidney function, were decreased. Researchers concluded that “this study suggests that vitamin C is a valuable tool to protect against [gentamicin] induced nephrotoxicity, by reducing reactive oxygen species and increasing nitric oxide.”
(Clinical Nutrition, April 2014)

LINK to ABSTRACT Ascorbic acid reduces gentamicin-induced nephrotoxicity in rats through the control of reactive oxygen species. 

CLINICAL UPDATE – Micronutrient supplementation shows promise for adults with ADHD

In this double-blind randomized controlled trial, 80 adults with ADHD were given either a potent multi-micronutrient supplement or placebo for eight weeks. When evaluated by clinicians, it was found that those on the micronutrient regimen showed significant more clinical improvement than those on placebo. Furthermore, those who began treatment with moderate to severe depression showed the most clinical improvement when supplemented. No adverse events were reported.
(British Journal of Psychiatry, January 2014)

LINK to ABSTRACT Vitamin-mineral treatment of attention-deficit hyperactivity disorder in adults: double-blind randomised placebo-controlled trial.